Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued Salvage Anti-Retroviral Therapy With Abacavir, Amprenavir, and Efavirenz
NCT00001758Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 1997
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abacavir, amprenavir and efavirenz in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Nov 1997; status: completed.
02
Drugs
abacaviramprenavirefavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00001758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001758.